Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of “Hold” by Analysts

Shares of Pulmonx Corporation (NASDAQ:LUNG) have received a consensus rating of “Hold” from the ten ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $6.8071.

A number of equities analysts recently issued reports on the company. Lake Street Capital reduced their target price on Pulmonx from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, October 28th. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 target price on shares of Pulmonx in a report on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday, January 22nd.

Pulmonx Trading Up 3.5%

Shares of Pulmonx stock opened at $1.47 on Monday. The firm’s 50 day simple moving average is $2.01 and its two-hundred day simple moving average is $1.80. The firm has a market capitalization of $60.64 million, a price-to-earnings ratio of -1.04 and a beta of 0.07. Pulmonx has a 12-month low of $1.31 and a 12-month high of $9.37. The company has a current ratio of 4.86, a quick ratio of 4.15 and a debt-to-equity ratio of 0.62.

Institutional Investors Weigh In On Pulmonx

Hedge funds have recently added to or reduced their stakes in the business. Vestal Point Capital LP purchased a new position in shares of Pulmonx during the 3rd quarter valued at about $1,345,000. Bank of America Corp DE grew its holdings in Pulmonx by 556.6% during the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock worth $1,246,000 after acquiring an additional 407,971 shares during the period. GSA Capital Partners LLP raised its position in Pulmonx by 78.3% during the third quarter. GSA Capital Partners LLP now owns 755,467 shares of the company’s stock valued at $1,224,000 after acquiring an additional 331,742 shares in the last quarter. Birchview Capital LP acquired a new position in Pulmonx in the fourth quarter valued at approximately $554,000. Finally, Westfield Capital Management Co. LP acquired a new position in Pulmonx in the fourth quarter valued at approximately $409,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.